Smith+Nephew announces results for its REGENETEN Bioinductive Implant from a recently completed randomized controlled trial, RCT. Published online in Arthroscopy in December, the report concluded that at one-year, medium and large full-thickness rotator cuff tears repaired and augmented with the REGENETEN Bioinductive Implant had better tendon healing compared to the standard of care, as evidenced by: A significantly lower re-tear rate; A three times lower risk of re-tear; No difference in the number of serious or minor complications. The blinded, multi-centre RCT compared the healing rate of full-thickness rotator cuff tears repaired with and without augmentation with the REGENETEN Bioinductive Implant.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SNN:
- New study confirms Smith+Nephew’s REGENETEN™ Bioinductive Implant reduces full-thickness rotator cuff re-tear rates¹ by 68%
- Smith & Nephew price target raised to 1,380 GBp from 1,360 GBp at Morgan Stanley
- Smith & Nephew assumed with a Buy at Jefferies
- Smith & Nephew upgraded to Equal Weight from Underweight at Barclays